THC Prevents MDMA Neurotoxicity in Mice

Clara Touriño1, Andreas Zimmer2, Olga Valverde1*

1 Departament de Ciències Experimentals i de la Salut, Grup de Recerca en Neurobiologia del Comportament (GRNC), Universitat Pompeu Fabra, Barcelona, Spain
2 Department of Molecular Psychiatry, University of Bonn, Bonn, Germany

Abstract

The majority of MDMA (ecstasy) recreational users also consume cannabis. Despite the rewarding effects that both drugs have, they induce several opposite pharmacological responses. MDMA causes hyperthermia, oxidative stress and neuronal damage, especially at warm ambient temperature. However, THC, the main psychoactive compound of cannabis, produces hypothermic, anti-inflammatory and antioxidant effects. Therefore, THC may have a neuroprotective effect against MDMA-induced neurotoxicity. Mice receiving a neurotoxic regimen of MDMA (20 mg/kg ×4) were pretreated with THC (3 mg/kg ×4) at room (21°C) and at warm (26°C) temperature, and body temperature, striatal glial activation and DA terminal loss were assessed. To find out the mechanisms by which THC may prevent MDMA hyperthermia and neurotoxicity, the same procedure was carried out in animals pretreated with the CB1 receptor antagonist AM251 and the CB2 receptor antagonist AM630, as well as in CB1, CB2 and CB1/CB2 deficient mice. THC prevented MDMA-induced hyperthermia and glial activation in animals housed at both room and warm temperature. Surprisingly, MDMA-induced DA terminal loss was only observed in animals housed at warm but not at room temperature, and this neurotoxic effect was reversed by THC administration. However, THC did not prevent MDMA-induced hyperthermia, glial activation, and DA terminal loss in animals treated with the CB1 receptor antagonist AM251, neither in CB1 and CB1/CB2 knockout mice. On the other hand, THC prevented MDMA-induced hyperthermia and DA terminal loss, but only partially suppressed glial activation in animals treated with the CB2 cannabinoid antagonist and in CB2 knockout animals. Our results indicate that THC protects against MDMA neurotoxicity, and suggest that these neuroprotective actions are primarily mediated by the reduction of hyperthermia through the activation of CB1 receptor, although CB2 receptors may also contribute to attenuate neuroinflammation in this process.

Introduction

3,4-Methylenedioxyxymethamphetamine (MDMA), commonly known as ecstasy, is a widely used recreational drug with low addictive potential, but with severe neurotoxic effects after prolonged use [1]. MDMA produces the loss of 5-HT nerve terminals when administered to primates or rats [2,3], and the degeneration of dopamine (DA) nerve terminals when administered to mice [4]. MDMA also induces hyperthermia [5], which enhances neurotoxicity. In addition, MDMA-induced hyperthermia increases at warm ambient temperature, what, consequently, aggravates axonal degeneration. High temperature enhances the formation and uptake of MDMA toxic metabolites that increase oxidative stress [6], causing nerve terminal damage [7,8], and leading to neuroinflammation manifested by glial activation [9,10], and eventually axonal degeneration. The strong influence of ambient temperature on MDMA neurotoxicity is of clinical interest since MDMA is frequently consumed in dance clubs with warm ambient temperatures [11], where the neurotoxic effects of the drugs may be exacerbated. One of the most effective mechanisms to minimize MDMA neurotoxicity is to reduce hyperthermia by decreasing ambient temperature [12] or using anhythmic drugs to control body temperature [9]. However, these drugs are rarely consumed by MDMA users. Interestingly, one of the drugs most frequently consumed together with MDMA is cannabis [13,14]. Δ2-tetrahydrocannabinol (THC), the main psychoactive compound of cannabis, has widely reported hypothermic [15], anti-inflammatory [16] and antioxidant [17] properties. Indeed, MDMA and THC show many opposite pharmacological effects. MDMA causes hyperlocomotion, hyperthermia, anxiety, and neurotoxicity [5], whereas THC induces hypolocomotion, hypothermia, anxiolytic, and neuroprotective properties [15]. Several studies in animal models demonstrate that the combination of MDMA and THC counterbalances many of their pharmacological effects. THC attenuated MDMA-induced hyperlocomotion, hyperthermia, and anxiety in rats [18], and MDMA reduced THC withdrawal syndrome in mice [19]. However, the neuroprotective effects of THC on MDMA neurotoxicity have not yet been explored. The opposite effects of cannabis and MDMA suggest that THC may provide some degree of protection against the neurotoxic effects of MDMA [20,21]. Therefore, in the present study, we investigate if hypothermic and neuroprotective properties of THC may prevent the neurotoxic effects of MDMA in mice.

Materials and Methods

Animals

We used 9 to 12 week old male C57BL/6 mice for this study. Mice were either wild-type (Charles River, France) or deficient in
the CB₁ and/or CB₂ cannabinoid receptors [22,23]. All animals were housed in a temperature (21°C or 26±1°C), humidity (55%±10%), and light-cycle controlled room.

Food and water were available ad libitum. Light was on between 8:00 am and 8:00 pm, and the experiments took place during the light phase. All animal care and experimental procedures were conducted according to the guidelines of the European Communities Directive 2003/66/EC regulating animal research and were approved by the local ethical committee (CEEA-PRBB).

Drugs
MDMA hydrochloride (Lipomed, A.G., Arlesheim, Switzerland) was dissolved in 0.9% saline and administered at 20 mg/kg, i.p. four times every 2 h. THC (THC Pharm, Frankfurt, Germany) was dissolved in a solution of 5% ethanol, 5% cremophor EL (Sigma Chemical, Madrid, Spain) and 90% physiological saline (0.9%), and administered at 3 mg/kg, i.p. 1 h before each MDMA injection. The CB₁ receptor antagonist AM251 and the CB₂ receptor antagonist AM630 (Tocris, Imalge`ne 1000, Rhoˆne Me`rieux, Lyon, France) and xylazine (10000°, Rhône Mérieux, Lyon, France) and yazine hydrochloride (20 mg/kg; Sigma Chemical Co., Madrid, Spain) were mixed and dissolved in ethanol and water (1:9). This anesthetic mixture was injected in a volume of 0.2 ml/10 g body weight i.p., and used for intracardiac perfusion.

Experimental Procedure
Animals were injected with MDMA (20 mg/kg, i.p.) or saline every 2 h for a total of 4 injections. One hour before each MDMA administration, animals received an injection of THC (3 mg/kg, i.p.) or its corresponding vehicle. A group of animals were also pretreated with the CB₁ receptor antagonist AM 251 or the CB₂ receptor antagonist AM 630 15 min before each THC injection. Body temperature was determined 30 min after the first MDMA injection. 48 h after the last MDMA injection, animals were sacrificed for immunostaining or western blot analysis.

Body Temperature
Rectal temperature was measured in animals housed at 21 and at 26±1°C and treated with THC and MDMA or their corresponding vehicles. Body temperature was measured by placing an electronic thermocouple flexible rectal probe (Panlab, Madrid, Spain) in the rectum for 10 s. Temperature was measured 30 min after the first MDMA injection. In order to determine the mechanism by which THC prevents MDMA-induced hyperthermia, two additional experiments were performed; (1) temperature was recorded in animals housed at 26±1°C and treated with the CB₁ receptor antagonist AM251 or the CB₂ receptor antagonist AM630, at 1 mg/kg 15 min before THC injection, and (2) body temperature was measured in CB₁, CB₂ and double CB₁/CB₂ knockout mice housed 26±1°C and treated with THC and MDMA.

Immunostaining
Activated microglia and astrocytes, and DA axons were identified by immunohistochemistry in the striatum of animals housed at 21 and 26±1°C and treated with MDMA and THC. Mice were anesthetized 48 h after the last MDMA injection with a ketamine/xylazine mixture and transcardially perfused with 0.1 M phosphate buffer containing 4% paraformaldehyde. Brains were removed and postfixed in the same solution for four hours and cryoprotected in 30% sucrose overnight. After freezing in dry ice, brains were sliced into 30-μm thick coronal sections containing the striatum. Sections were preincubated for 30 min in 20% H₂O₂ (Sigma-Aldrich, Spain), and then incubated for 2 h in a solution of 3% normal goat serum (Vector Laboratories, Inc., Burlingame, CA) and 0.3% triton X-100 (Sigma-Aldrich, Spain). Activated microglia was detected with rat anti-mouse CD11b (1:100; Serotec, Oxford, UK), astrocytes were detected with polyclonal rabbit anti-glial fibrillary acidic protein (1:1000; GFAP; Dako, Glostrup, Denmark), and DA axons were detected with mouse anti-TH (1: 5000; Sigma-Aldrich, Spain). To visualize anti-CD11b and anti-TH primary antibodies, biotinylated secondary antibodies to rat or mouse Igs were applied for 1 h, followed by incubation with avidin/biotin reagent (Vector Laboratories, Inc., Burlingame, CA) for 2 h. Sections were stained with diaminobenzidine-HCl (DAB) and H₂O₂. A fluorescent Alexa Fluor® 488 secondary antibody (Invitrogen, Eugene, OR) was used to visualize anti-GFAP primary antibody. Analysis of CD11b and GFAP immunostaining in the striatal region was carried out with Image J software [24]. Briefly, the area comprising the striatum was selected and the background was subtracted by adjusting detection threshold density considering just the signal density above the threshold. The number of pixels per area was measured automatically, and the percentage of stained area was determined. Measurements were performed in 3 different slices from the same animal, the average was calculated, and the data were expressed as percentage of the stained area.

Western Blot Analysis
Analysis of protein levels of tyrosine hydroxylase (TH), tryptophan hydroxylase (TRH), serotonin transporter (SERT), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the striatum, as well as the levels of TrH and SERT in prefrontal cortex and hippocampus of animals housed at 21 or 26±1°C and treated with THC and MDMA were analyzed by western blot. Animals were sacrificed 48 h after the last MDMA injection, and the striatum was dissected. Samples from all animals were processed in parallel to minimize inter-assay variations. Frozen brain areas were dounce-homogenized in 30 volumes of lysis buffer (50 mmol/L Tris-HCl pH 7.4, 150 mmol/L NaCl, 1% glycerol, 1 mmol/L EDTA, 1 μg/mL aprotinin, 1 μg/mL leupeptine, 1 μg/mL pepstatin) plus 1% Triton X-100. After 10 min incubation at 4°C, samples were centrifuged at 16000 g for 30 min to remove insoluble debris. Supernatant protein contents were determined by DC-micro plate assay (Bio-Rad, Madrid, Spain), following the manufacturer’s instructions.

Equal amounts of brain lysates were mixed with denaturing 5X Laemmli loading buffer and boiled for 5 min at 95°C. Samples with equal amounts of total protein (20 μg per lane) were separated in 10% sodium dodecyl sulfate-polyacrylamide gel before electrophoretic transfer onto immobilon membrane (Millipore, Billerica MA). Membranes were blocked for 1 h at room temperature in Tris-buffered saline (TBS) (100 mmol/L NaCl, 10 mmol/L Tris, pH 7.4) with 0.1% Tween-20 (TBS-T) and 5% non-fat milk. Afterwards, membranes were incubated for 2 h with mouse anti-TH (1:5000; Sigma-Aldrich, Spain), rabbit anti-SERT (1:1000), sheep anti TRH (1:1000) (Millipore, Billerica MA), and mouse anti-GAPDH (1:5000) (Santa Cruz Biotechnology, Santa Cruz, CA) primary antibodies. Bound antibodies were detected with horseradish peroxidase-conjugated and anti-mouse, anti-rabbit (Pierce, Spain; diluted), and anti-sheep (1:2500; Santa Cruz Biotechnology, Santa Cruz, CA) secondary antibodies and
visualized by enhanced chemiluminescence detection (Super-Signal, Pierce, Spain). Only immunobLOTS showing similar amount of GAPDH in all lanes were considered. The relevant immuno-reactive bands were quantified after acquisition on a Chemiluminescent Imaging with Chemi-Doc XRS, controlled by Image Gauge software (Fuji, Japan). Data was expressed as the percentage of the band intensity compared to the control.

**Statistical Analysis**

Differences in body temperature, and microglia and astrocytes staining between the different genotypes were compared by two-way ANOVA with treatment and genotype as between-subjects factors of variation, followed by one-way ANOVA and subsequent post hoc analysis (Tukey’s test). Differences in body temperature and glial staining between animals housed at different ambient temperatures were compared by two-way ANOVA with treatment and ambient temperature as between-subjects factors of variation, followed by one-way ANOVA (Table 1 and 2). Differences in body temperature of animals housed at 21°C, and microglia and astrocytes staining, TH, TrH and SERT protein levels of animals housed at 26°C were compared by one-way ANOVA followed by post hoc analysis (Tukey’s test). In all the experiments, differences were considered significant if the probability of error was less than 5%.

**Results**

**Effects of THC on MDMA Treatment at Room Temperature (21±1°C)**

**THC reverses the moderated hyperthermia induced by MDMA at room temperature.** A baseline body temperature of 37.5±0.08°C was recorded in all animals housed at 21±1°C. One hour after baseline, animals were injected with THC or vehicle followed by MDMA or saline. Body temperature was measured 30 min after MDMA injection (Fig. 1). Animals treated with MDMA showed a statistically significant increase in body temperature compared to the vehicle-treated group (p<0.05). In contrast, a reduction of body temperature was observed in animals treated with THC (p<0.05). Likewise, THC significantly reduced body temperature in MDMA-treated animals when compared to MDMA-treated mice (p<0.001), and when compared with the saline-treated group (p<0.001) (Table 1).

**THC prevents microglia and astrocytes activation in MDMA-treated mice, mainly by CB1 but also by CB2 receptor-mediated mechanism.** The activation of both microglia and astrocytes was evaluated in the striatum of mice housed at room temperature (21±1°C) and treated with THC and MDMA. Staining for activated microglia with an antibody for CD11b (Fig. 2a-c) and for astrocytes with an antibody for GFAP (Fig. 3a-c) showed that MDMA induced a marked glial activation and that THC completely prevented microglia and astrocytes activation induced by MDMA administration. THC alone had no effect on microglia or astrocytes staining (data not shown). To determine the mechanism by which THC prevents microglia and astrocytes activation, CB1 (Fig. 2 and 3d-f), CB2 (Fig. 2 and 3g-i) and double CB1/CB2 (Fig. 2 and 3j-l) knockout mice were treated with a THC and MDMA regimen. THC was unable to inhibit microglia and astrocytes activation in CB1 and CB1–CB2 mutant mice (Fig. 2 and 3d–f and j–l). However, THC partially suppressed microglial activation in CB2 knockout mice treated with MDMA, and a similar effect was observed with astrocytes activation (Fig. 2 and 3g–i). These results suggest that THC prevents MDMA-induced glial activation by activating CB1 receptor, and that the activation of CB2 receptor by THC partially contributes to the suppression of MDMA-induced microglial and astrocytes activation (Table 1 and 2).

**MDMA does not cause visible damage in striatal DA terminals at room temperature.** To evaluate DA axonal damage, TH levels were evaluated in the striatum of mice treated with THC and MDMA, and housed at 21±1°C (Fig. 4). The structure of the striatum (Fig. 4a) and the content of TH (Fig. 4b) were similar between MDMA and saline treated animals (Table 1). These results suggest that MDMA treatment at room temperature does not cause a significant loss of DA terminals. THC alone had no effects on the structure of the striatum or the levels of TH (data not shown).

**Effects of THC on MDMA Treatment at Warm Temperature (26±1°C)**

**THC reverses MDMA induced hyperthermia at warm temperature by a CB1 receptor mechanism.** Body temperature was measured in animals housed at 26±1°C. These animals showed a baseline core temperature of 37.8±0.05°C, which was similar to basal body temperature of animals housed at 21°C (37.5±0.08°C). This result suggests that increased ambient temperature does not affect basal body temperature. After baseline recordings, wild-type animals were injected with THC followed by MDMA 1 h later, and body temperature was measured 30 min after the MDMA injection (Fig. 5a).

MDMA administration at 26°C produced a significant hyperthermia when compared to the vehicle-treated group (p<0.001), whereas THC alone produced significant hypothermia when compared with control animals (p<0.01). However, body temperature in MDMA-treated animals receiving THC was significantly lower than in animals treated with MDMA alone (p<0.01) and similar to animals treated with vehicle. Thus, THC significantly reduced MDMA-induced hyperthermia at warm temperature (Table 2).

Body temperature of animals housed at 21°C and 26°C were compared (Fig. 5b). No significant differences in core temperature were observed between animals housed at 21°C and at 26°C and treated with vehicle or THC. However, MDMA-treated animals showed a significant enhancement in body temperature when housed at 26°C (p<0.001), and this effect was also observed in MDMA-treated animals receiving THC (p<0.01) (Table 1 and 2). These results indicate that warm ambient temperature potentiates the hyperthermic effects of MDMA, but does not affect hypothermic effects of THC.

Body temperature was also measured in animals pretreated with the CB1 receptor antagonist AM251 (Fig. 5c) and the CB2 receptor antagonist AM630 (Fig. 5d) receiving THC and MDMA and housed at 26±1°C. AM251 blocked the effect of THC on body temperature. Therefore, THC did not prevent MDMA-induced hyperthermia in these mice. Conversely, THC induced hypothermia and prevented MDMA-induced hyperthermia in animals pretreated with the CB2 antagonist AM630 (Table 1).

Body temperature was also recorded in CB1, CB2 and double CB1/CB2 knockout mice administered with THC and MDMA (Fig. 5a). Two-way ANOVA (Table 2), and subsequent post hoc (Tukey’s test) analysis revealed that vehicle-treated CB1, CB2, and double CB1/CB2 knockout mice showed similar body temperature than wild-type mice. Moreover, MDMA induced similar hyperthermia in CB1, CB2 and CB1/CB2 knockout mice than in wild-type mice. On the contrary, THC induced hyperthermia in wild-type and CB2 knockout mice, but not in CB1 and CB1–CB2 deficient mice. Consequently, while THC prevented MDMA-induced hyperthermia in wild-type and CB2 knockout mice, it was unable to prevent MDMA-induced hyperthermia in mice.
deficient in the CB1 and CB1/CB2 receptor. Thus, THC prevents MDMA-induced hyperthermia through the activation of CB1 receptor.

THC prevents microglia and astrocytes activation in MDMA-treated mice housed at warm temperature. Microglia and astrocytes activation was evaluated in the striatum of animals housed at 26°C after treatment with THC and MDMA (Figure 6). Microglia (Fig. 6a) and astrocytes (Fig. 6b) were significantly activated in MDMA-treated animals housed at 26°C. However, THC suppressed MDMA-induced microglia and astrocytes activation in animals housed at warm temperature. After, MDMA-induced microglia and astrocytes activation of animals housed at 26°C was compared with animals housed at 21°C. Although the intensity of glial activation was similar at 21 and at 26°C, the area stained with CD11b and astrocytes activation was significantly wider in animals housed at 26°C (Table 2).

THC protects against DA terminal loss induced by MDMA at warm ambient temperature by CB1 receptor activation. The integrity of DA terminals was evaluated in animals housed at 26°C treated with THC and MDMA.

| Table 1. One-way ANOVA calculated for body temperature, CD11b and GFAP staining and TH levels at 21 and 26°C. |
|---------------------------------|-------------------|-------------------|-------------------|
| Factor                         | F-value           | p-value           |
| Body temperature (21°C)        |                   |                   |
| Treatment                      |                   |                   |
| CD11b (21°C)                   |                   |                   |
| Genotype                       |                   |                   |
| vehicle                        |                   |                   |
| MDMA                           |                   |                   |
| THC+MDMA                       |                   |                   |
| Treatment                      |                   |                   |
| WT                             | F(1, 39) = 20.595 | < 0.001           |
| CB1 KO                         | F(3, 27) = 38.656 | < 0.001           |
| CB2 KO                         | F(3, 27) = 38.656 | < 0.001           |
| CB1-CB2 KO                     | F(3, 27) = 38.656 | < 0.001           |
| GFAP (21°C)                    |                   |                   |
| Genotype                       |                   |                   |
| vehicle                        |                   |                   |
| MDMA                           |                   |                   |
| THC+MDMA                       |                   |                   |
| Treatment                      |                   |                   |
| WT                             | F(1, 21) = 51.671 | < 0.001           |
| CB1 KO                         | F(1, 21) = 51.671 | < 0.001           |
| CB2 KO                         | F(1, 21) = 51.671 | < 0.001           |
| CB1-CB2 KO                     | F(1, 21) = 51.671 | < 0.001           |
| TH (21°C)                      |                   |                   |
| Treatment                      |                   |                   |
| Body temperature (26°C)        |                   |                   |
| Genotype                       |                   |                   |
| vehicle                        |                   |                   |
| THC                            |                   |                   |
| MDMA                           |                   |                   |
| THC+MDMA                       |                   |                   |
| Treatment                      |                   |                   |
| WT                             | F(2, 21) = 23.044 | < 0.001           |
| CB1 KO                         | F(2, 21) = 23.044 | < 0.001           |
| CB2 KO                         | F(2, 21) = 23.044 | < 0.001           |
| CB1-CB2 KO                     | F(2, 21) = 23.044 | < 0.001           |
| AM251                          |                   |                   |
| TH levels (26°C)               |                   |                   |
| Treatment                      |                   |                   |
| Body temperature (21 vs 26°C)  |                   |                   |
| Ambient temperature            |                   |                   |
| vehicle                        |                   |                   |
| THC                            |                   |                   |
| MDMA                           |                   |                   |
| THC+MDMA                       |                   |                   |
| Treatment                      |                   |                   |
| WT                             | F(1, 21) = 15.119 | < 0.001           |
| CB1 KO                         | F(1, 21) = 15.119 | < 0.001           |
| CB2 KO                         | F(1, 21) = 15.119 | < 0.001           |
| CB1-CB2 KO                     | F(1, 21) = 15.119 | < 0.001           |
| AM251                          |                   |                   |
| AM630                          |                   |                   |
| Treatment                      |                   |                   |
| CD11b (26°C)                   |                   |                   |
| Treatment                      |                   |                   |
| GFAP (26°C)                    |                   |                   |
| Treatment                      |                   |                   |
| TH levels (26°C)               |                   |                   |
| Treatment                      |                   |                   |
| AM251                          |                   |                   |
| AM630                          |                   |                   |

One-way ANOVA for genotype, treatment or ambient temperature as between-subject factors. See Materials and methods for details. WT: wild-type; KO: knockout; n.s.: non-significant.
doi:10.1371/journal.pone.0009143.t001
Finally, TH levels were evaluated in CB1, CB2 and double CB1/CB2 knockout mice administered with THC and MDMA (Fig. 7b). Vehicle-treated CB1, CB2 and double CB1-CB2 knockout mice showed similar TH levels than wild-type mice. In contrast, THC prevented MDMA-induced hyperthermia in wild-type and CB2 knockout mice, but it was unable to prevent MDMA-induced DA terminal loss in mice deficient in the CB1 and CB2 receptor. In conclusion, THC protects against MDMA-induced DA axonal degeneration through the activation of CB1 receptor.

Discussion

In this study, we show that THC prevents MDMA neurotoxicity not only at room temperature, in which brain damage is mild, but also at warm temperature, where the neurotoxic effects of MDMA are strongly enhanced [7,8]. Many reports describe that MDMA-induced neurotoxicity is directly related to its hyperthermic effect, and that MDMA-induced hyperthermia is proportional to the environmental temperature [8]. For that reason, we tested the hypothermic and neuroprotective effects of THC on MDMA neurotoxicity at both 21°C (room temperature) and 26°C (warm temperature). The hypothermic effects of THC are well known [15], suggesting that THC might be a good candidate to prevent MDMA-induced hyperthermia and neurotoxicity. Furthermore, the anti-inflammatory properties of THC have been widely reported, and cannabimimetic drugs have been shown to exhibit strong neuroprotective effects on a wide variety of central nervous system (CNS) disorders [25]. Thus they might contribute to attenuate MDMA neurotoxicity. Additionally, THC seems to have neuroprotective effects mediated by receptor independent mechanisms due to its antioxidant properties [17,26]. Cannabis, whose main psychoactive compound is THC, is a drug consumed by 95% of MDMA users. The frequent co-use of both drugs makes it particularly interesting to study the effects of their combination. Indeed, previous studies describe the effects of THC and MDMA together in animal models of locomotor activity, temperature, anxiety [18], reward [27] and THC-dependence [19]. However, the neuroprotective effects of THC on MDMA neurotoxicity have never been reported. In addition, the dose of THC used in this study (3 mg/kg, i.p.) could be considered a dose consumed by regular moderate cannabis users, and for that reason similar doses are used in the previously reported animal studies [18,27].

First, we studied the effects of THC on MDMA-induced hyperthermia. Mice housed at room temperature (21°C) showed a moderated hyperthermia when exposed to MDMA, but severe hyperthermia when room temperature was raised to 26°C. When THC was administered to MDMA-treated animals, hyperthermia...
was prevented in both, mice housed at 21°C and at 26°C. Consistent with our results, previous studies described that THC attenuated MDMA-mediated hyperthermia in rats [18]. Moreover, unlike MDMA, the effects of THC on body temperature were not affected by ambient temperature. These data indicate that the mechanisms by which THC reduces body temperature are different from those mediating MDMA-induced hyperthermia. While THC specifically activates CB1 receptors in the preoptic anterior hypothalamus causing hypothermia [28], MDMA impairs thermoregulation by altering DA and 5-TH systems [29]. To find out the mechanism by which THC prevents MDMA-induced hyperthermia, both THC and MDMA were administered to animals pretreated with the CB1 receptor antagonist AM251 or the CB2 receptor antagonist AM630, as well as in mice lacking the CB1, CB2, or both cannabinoid receptors. THC was unable to prevent MDMA-induced hyperthermia in mice treated with AM251 or in mice deficient in the CB1 receptor. These data are consistent with previous studies that described the inability of THC to prevent MDMA-induced hyperthermia in animals pretreated with the CB1 antagonist rimonabant. On the contrary, neither the administration of AM630 nor the deletion of CB2 receptor gene modified the ability of THC to prevent MDMA-induced hyperthermia. These results suggest that the hypothermic effects of THC, which are mediated by the activation of CB1 receptor [30], are responsible for preventing MDMA-induced hyperthermia, and that CB2 receptor has not a predominant role on this effect. Furthermore, there is evidence that the absence of CB1 receptor also participates in the expression of MDMA induced hyperthermia [31], indicating that not only the pharmacological activation of this receptor, but its physiological function plays an important role in the hyperthermic effects of MDMA.

Figure 2. THC prevents MDMA-induced microglial activation through CB1 and CB2 receptor activation. Upper panel: CD11b staining in the striatum of wild-type (a–c), CB1 (d–f), CB2 (g–i), and double CB1/CB2 (j–l) knockout mice treated with MDMA (20 mg/kg, i.p.) and THC (3 mg/kg, i.p.), and housed at 21±1°C. Animals were sacrificed and brains removed 48 h after the last injection. Scale bar, 100 μm. Lower panel: Data on microglial staining quantification (lower panel) are expressed as mean ± SEM of percentage of stained area (n=3–6). * p<0.05, ** p<0.01, *** p<0.001 when compared with vehicle-treated group. ⋆ p<0.05, ⋆⋆⋆ p<0.01, when compared with MDMA-treated group. §§§ p<0.001, when compared with wild-type group (Tukey’s test).

doi:10.1371/journal.pone.0009143.g002
Usually, MDMA-induced hyperthermia is related to brain damage. Astrocytes and microglia are activated with minimal alterations in the CNS, and are considered sensitive markers of brain damage. For that reason, we evaluated the effects of THC on MDMA-induced glial activation. MDMA induced a strong activation of microglia and astrocytes in animals housed at both 21 \( ^\circ \)C and 26 \( ^\circ \)C, as previously reported [9,10]. Nevertheless, the administration of THC significantly reduced glial activation in animals housed at both 21 and 26 \( ^\circ \)C. These results agree with previous studies describing that the decrease of MDMA-induced hyperthermia also attenuates glial activation [9,32]. However, the well known anti-inflammatory properties of THC may also contribute to the reduction of MDMA-induced glial activation. To find out if THC inhibited MDMA-induced microglial and astrocytes activation by preventing hyperthermia or by reducing inflammation, glial activation was evaluated in CB1, CB2 and double CB1/CB2 receptor deficient mice. THC was unable to prevent glial activation in CB1 and double CB1/CB2 receptor deficient mice. CB1 receptor is necessary to induce the hypothermic properties of THC, which would prevent MDMA hyperthermia and, consequently, cell damage. Furthermore, THC only partially suppressed MDMA-induced astrocytes and microglia activation in CB2 receptor deficient mice. Microglia cells express CB2 cannabinoid receptor [33], which mediated the anti-inflammatory properties of THC [34]. In many cases, severe microglia activation exacerbates inflammation and brain damage instead of reducing it due to the high amount of inflammatory mediators, such as cytokines and nitric oxide, released by these cells [35]. Thus, the activation of CB2 receptor by THC contributes to attenuate microglial activation and, as a result, to reduce cell damage. Thus, both CB1 and CB2 receptors mediate the THC-induced prevention of MDMA-induced glial activation and cell damage. Furthermore, the receptor-independent antioxidant properties of THC may also contribute to the reduction of MDMA neurotoxic effects. This result indicates that antioxidant properties of THC do not contribute to reduce MDMA neurotoxic effects.

**Figure 3. THC prevents MDMA-induced astrocytes activation through CB1 and CB2 receptor activation.** Upper panel: GFAP staining in the striatum of wild-type (a–c), CB1 (d–f), CB2 (g–i), and double CB1/CB2 (j–l) knockout mice treated with MDMA (20 mg/kg, i.p.) and THC (3 mg/kg, i.p.), housed at 21 \( ^\circ \)C. Animals were sacrificed and brains removed 48 h after the last injection. Scale bar, 100 \( \mu \)m. Lower panel: Data on astrocytes staining are expressed as mean \( \pm \) SEM of percentage of stained area (n = 3–6). \* \( p < 0.05 \), \** \( p < 0.01 \), \*** \( p < 0.001 \) when compared with vehicle-treated group. \*** \( p < 0.001 \), when compared with MDMA-treated group. \*** \( p < 0.001 \), when compared with wild-type group (Tukey's test). doi:10.1371/journal.pone.0009143.g003
To evaluate if the MDMA-induced brain damage that triggered glial activation resulted in DA axonal loss, we assessed the integrity of DA striatum terminals. DA axons were stained and TH levels were measured in the striatum of mice treated with THC and MDMA and housed at 21 or 26°C. Surprisingly, mice treated with MDMA at 21°C did not show a significant alteration of striatum structure or decrease in TH levels. This result indicates that the cell damage and the consequent inflammation induced by MDMA in animals housed at 21°C were not strong enough to destroy DA nerve terminals. In contrast, MDMA-treated animals housed at 26°C showed an important alteration of striatum structure and a significant decrease of TH levels. These results agree with previous reports describing that the enhancement in MDMA-induced hyperthermia caused by warm ambient temperature also enhances MDMA neurotoxicity [8]. Strikingly, MDMA induced a strong microglia and astrocytes activation at both 21 and 26°C ambient temperatures. Microglia and astrocytes are extremely sensitive to even small pathological changes in the CNS [36], whereas a strong change is required to observe significant changes in striatum structure and TH levels. Thus, the moderated hyperthermia induced by MDMA to animals housed at 21°C caused mild neuronal damage, which elicited an inflammatory reaction, but did not destroy DA axons or reduce TH levels. On the contrary, the strong hyperthermia induced by MDMA at 26°C caused severe neuronal damage that triggered a marked glial activation, an important alteration of the striatum structure, and a significant reduction of TH levels. Our results are supported by other studies showing that warm ambient temperature enhances MDMA neurotoxicity by promoting the formation of neurotoxic derivatives [7], and by enhancing the uptake of these metabolites inside the brain.

Figure 4. MDMA does not decrease TH levels in the striatum at room temperature. TH immunostaining (a) and protein levels (b) in the striatum of animals treated with THC (3 mg/kg, i.p.) and MDMA (20 mg/kg, i.p.) housed at 21±1°C. Animals were sacrificed and tissue was removed 48 h after the last injection. A representative TH immunostaining (a) is shown. TH band densities (b) were quantified. Data are expressed as mean ± SEM of percentage of density compared to controls (n = 3).

doi:10.1371/journal.pone.0009143.g004
Figure 5. THC prevents MDMA-induced hyperthermia at warm temperature by activating CB1 receptor. Effects of pretreatment with THC (3 mg/kg, i.p.) on MDMA (20 mg/kg, i.p.)-induced hyperthermia in (a) wild-type, CB1, CB2, and double CB1/CB2 knockout animals housed at 26 ± 1°C, (b) wild-type animals treated with THC and MDMA at 21 and 26 ± 1°C, and wild-type animals treated with (c) AM251 or (d) AM630, THC and MDMA at 26°C. Body temperature was measured 30 min after MDMA injection (90 min after THC injection). Data are expressed as mean ± SEM of the body temperature increase (n = 6–7). All values are expressed as mean ± SEM. ** p < 0.01, *** p < 0.001 when compared with vehicle-treated group. $p < 0.05, §§ p < 0.01, §§§ p < 0.001 when compared with wild-type animals or animals housed at 21 ± 1°C (Tukey’s test or one-way ANOVA).

doi:10.1371/journal.pone.0009143.g005

Figure 6. THC prevents MDMA-induced glial activation at both room and warm temperature. CD11b (a) and GFAP (b) staining quantification in mice housed at 21 and 26 ± 1°C. Data are expressed as mean ± SEM of percentage of stained area (n = 3–7). *** p < 0.001 when compared with vehicle-treated group. $ p < 0.05, §§ p < 0.01, §§§ p < 0.001 when compared with MDMA-treated group. $ p < 0.05, §§ p < 0.01, §§§ p < 0.001 when compared with animals housed at 21 ± 1°C (Tukey’s test or one-way ANOVA).

doi:10.1371/journal.pone.0009143.g006
the cell [8,57]. Hence, the reduction of body temperature by THC may attenuate the formation and uptake of toxic metabolites and prevent MDMA neurotoxicity. Therefore, we evaluated the effect of THC on MDMA-induced DA axonal loss in the striatum of animals housed at 26°C. The striatum of animals treated with THC and MDMA showed similar structure and staining intensity compared with the striatum of saline-treated animals, whereas the striatum of MDMA-treated mice showed a decreased staining and an altered structure. In addition, TH levels in the striatum were similar between saline-treated animals and animals treated with both THC and MDMA, whereas they were strongly reduced in animals treated with MDMA. Thus, THC prevents the destruction of DA axons induced by MDMA at high ambient temperature. To find out the mechanism by which THC prevents DA axonal loss, animals treated with THC and MDMA were pretreated with the CB<sub>1</sub> antagonist AM251 and the CB<sub>2</sub>...
antagonist AM630. THC prevented MDMA-induced DA terminal loss in mice pretreated with AM630 but not with AM251. These results indicate that the activation of CB1 but not CB2 receptor is necessary for THC to prevent MDMA-induced DA axons destruction. Nevertheless, acute pharmacological blockade of either CB1 or CB2 receptors does not inhibit cannabinoid receptor permanently during all the process and axonal degeneration. For that reason, the mechanism by which THC prevents MDMA-induced axonal damage was also evaluated in CB1, CB2 and double CB1/CB2 knockout mice. CB1 and double CB1/CB2 knockout mice treated with THC and MDMA showed similar TH levels than mice treated with MDMA alone, suggesting that the hypothemic effects of THC mediated by CB1 receptor are responsible for preventing DA terminals destruction. However, no difference between CB1 knockout mice and double CB1-CB2 knockout mice treated with both THC and MDMA was observed. Furthermore, no difference between CB1 knockout mice and wild-type mice receiving THC and MDMA was observed. Additionally, we observed difference between CB1 knockout mice treated with THC and MDMA together and MDMA alone. Altogether, these results indicate that the anti-inflammatory properties of THC mediated by CB2 receptor do not significantly contribute to prevent DA terminal loss.

In summary, THC completely prevents MDMA-induced hyperthermia, glial activation and DA axonal loss by inducing CB1 receptor-mediated hypothermia. THC anti-inflammatory properties mediated by CB2 receptors also reduced microglia and astrocytes activation induced by MDMA. However, THC receptor-independent antioxidant properties do not seem to contribute to reduce MDMA neurotoxicity. Although it has been previously reported that other drugs reducing MDMA-induced hyperthermia also reduced MDMA neurotoxicity [9], these drugs are not used by potential MDMA users. On the contrary, 95% of MDMA users also consume cannabis [14,21] and, consequently, THC. Some clinical studies have shown that the use of cannabis and MDMA usually results in neurocognitive deficits and neuropsychiatric symptoms, especially in long-lasting heavy users [38–40]. However, clinical data suggest the possibility that THC may protect against the neurotoxic effects of MDMA, since several neurological symptoms were attenuated in THC and MDMA consumers when compared to pure MDMA users [21,41,42]. Indeed, the use of THC to prevent MDMA-induced hyperthermia and neurotoxicity does not seem to be an adequate measure. However, this study elucidates the consequences of drug polyuse which is one of the main concerns in the study of drugs of abuse, especially MDMA.

Author Contributions
Conceived and designed the experiments: CT OV. Performed the experiments: CT. Analyzed the data: CT. Contributed reagents/materials/analysis tools: AZ. Wrote the paper: CT OV.

References
1. Schmidt CJ (1987) Neurotoxicity of the psychedelic amphetamine, methylene-dioxymethamphetamine. J Pharmacol Exp Ther 240: 1–7.
2. Colado MI, O’Shea E, Granados R, Murray TK, Green AR (1997) In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA (‘ecstasy’) and p-chloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol 112: 891–900.
3. Hewitt KE, Green AR (1994) Chloromethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA (‘Ecstasy’) to rats. Neuropharmacology 33: 1593–1595.
4. Logan BJ, Laverty R, Sunderson WD, Yee YB (1989) Differences between rats and mice in MDMA (methylene-dioxymethamphetamine) neurotoxicity. Eur J Pharmacol 177: 227–234.
5. Green AR, Mehan AO, Elliott JM, O’Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or ‘Ecstasy’). Pharmaco Rev 55: 463–508.
6. Cadet JL, Krausova IN, Jayanthi S, Lyles J (2007) Neurotoxicity of substituted amphetamine: molecular and cellular mechanisms. Neurotox Res 11: 183–202.
7. Gotli-Allo B, Mathuna O, Segura M, Puerta E, Lasheiras B, et al. (2008) The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity. Psychopharmacology (Berl) 197: 263–278.
8. Malberg JE, Seiden LS (1989) Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 19: 5096–5099.
9. O’Callaghan JP, Miller DB (1994) Neurotoxicity profiles of substituted amphetamine in the C57BL/6J mouse. J Pharmacol Exp Ther 270: 741–751.
10. Thomas DM, Dosogiert J, Geddes TJ, Francescutto-Verbeeum D, Liu X, et al. (2008) Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci Lett 367: 349–354.
11. Green AR, Cross AJ, Goodwin GM (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or ‘Ecstasy’). Psychopharmacology (Berl) 119: 247–260.
12. O’Shea E, Orio I, Escobedo I, Sanchez V, Camarero J, et al. (2006) MDMA-induced neurotoxicity: long-term effects on 5-HT biosynthesis and the influence of ambient temperature. Br J Pharmacol 148: 778–785.
13. stroe J, Lee JE, Wechsler HI (2002) Increasing MDMA use among college students: results of a national survey. J Adolesc Health 30: 64–72.
14. Winstock AR, Griffiths P, Stewart D (2001) Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 64: 9–17.
15. Amen A (1999) The effects of cannabinoids on the brain. Prog Neurobiol 58: 315–348.
16. Formukong EA, Evans AT, Evans JF (1988) Anesthetic and antiinflammatory activity of constituents of Cannabis sativa L. Inflammation 12: 361–371.
17. Hampson AJ, Grimmaldi M, Axelrod J, Wink D (1990) Cannabinoid and Delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 87: 1095–1099.
18. Morey KC, Li KM, Hunt GE, Mallet PE, McGregor IS (2004) Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA (‘Ecstasy’) in rats. Neuropharmacology 46: 954–965.
19. Touriño C, Maldonado R, Valverde O (2007) MDMA attenuates THC withdrawal syndrome in mice. Psychopharmacology (Berl) 193: 75–84.
20. Daumann J, Schnitzer R, Weidemann J, Schnell K, Thron A, et al. (2003) Neural correlates of working memory in pure and polycyvalient ecstasy (MDMA) users. Neuroreport 14: 1983–1987.
21. Parrott AG, Milani RM, Gonzalez-Mayfrank E, Daumann J, Jury (2007) Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobehavioral interactions in recreational users. J Neural Transm.
22. Jia Z, Wanger JA, Varga K, Lake KD, Compton DR, et al. (1999) Cannabinoid-induced mesentric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A 96: 14136–14141.
23. Zimmer A, Zimmer AM, Hohlman AG, Herkenham M, Benzer T (1999) Increased mortality, hypothermia, and hypogalasias in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 96: 5780–5785.
24. Racz I, Nadal X, Alferink J, Banos JE, Rehfeld JH, et al. (2000) Crucial role of CB2 cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci 20: 12125–12130.
25. Sarne Y, Mechoalam R (2005) Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord 4: 677–684.
26. Chen Y, Back J (2000) Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J Pharmacol Exp Ther 293: 897–912.
27. Robledo P, Trigo JM, Panayi F, de la Torre R, Maldonado R (2007) Behavioural and neurochemical effects of combined MDMA and THC pharmacotherapy in mice. Psychopharmacology (Berl) 195: 253–264.
28. Rawls SM, Cabana J, Geller EB, Adler MW (2002) CB1 receptors in the preoptic anterior hypothalamus regulate WSN 53212 [4,5-dihydro-2-methyl-4-(5-morpholinomethyl)-1-(1-naphthalenylcarboxy)-6H-pyrrolo[3,2,1-i]quinolin-6-one]-induced hyperthermia. J Pharmacol Exp Ther 301: 963–968.
29. Green AR, O’Shea E, Colado MI (2004) A review of the mechanisms involved in the acute MDMA (‘ecstasy’) induced hyperthermic response. Eur J Pharmacol 500: 5–13.
30. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, et al. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401–404.
31. Touriño C, Ledent C, Maldonado R, Valverde O (2008) CB1 cannabinoid receptor modulates 3,4-methylenedioxymethamphetamine acute responses and reinforcement. Biol Psychiatry 63: 1030–1038.
32. Orio L, O’Shea E, Sanchez V, Pradillo JM, Escobedo I, et al. (2004) 3,4-Methylenedioxymethamphetamine increases interleukin-1beta levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5-HT depletion. J Neurochem 89: 1445–1453.

33. Munro S, Thomas KL, Bu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61–65.

34. Cabral GA, Raborn ES, Griffin L, Dennis J, Marziano-Cabral F (2008) CB2 receptors in the brain: role in central immune function. Br J Pharmacol 153: 240–251.

35. Hanisch UK, Kettenmann H (2007) Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10: 1387–1394.

36. Dissing-Olesen L, Ladeby R, Nielsen IH, Toft-Hansen H, Dalmau I, et al. (2007) Axonal lesion-induced microglial proliferation and microglial cluster formation in the mouse. Neuroscience 149: 112–122.

37. O’Shea E, Esteban B, Camarero J, Green AR, Colado MI (2001) Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA (‘ecstasy’) on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology 40: 65–74.

38. Indlekofer F, Peschatzek M, Daamen M, Glasmacher C, Lieb R, et al. (2008) Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol. J Psychopharmacol.

39. Karlsen SN, Spigset O, Sordial I (2008) The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine. Basic Clin Pharmacol Toxicol 102: 15–24.

40. Di Forti M, Morrison PD, Butt A, Murray RM (2007) Cannabis use and psychiatric and cognitive disorders: the chicken or the egg? Curr Opin Psychiatry 20: 249–254.

41. Milani RM, Parrott AC, Schiffano F, Turner JF (2005) Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms. Hum Psychopharmacol 20: 249–261.

42. Parrott AC, Gouzoulis-Meyfrank E, Rodgers J, Solowij N (2004) Ecstasy/MDMA and cannabis: the complexities of their interactive neuropsychobiological effects. J Psychopharmacol 18: 572–573.